UCB SA

Belgian biopharma UCB SA leads in neurology and immunology with blockbuster drugs Cimzia, Vimpat, Neupro, Evenity and partnerships with Sanofi, Amgen, Biogen, plus a Stanford collaboration, driving growth via global reach and contract manufacturing.

Headquarters: Belgium (BEL)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 8,600
HQ: Brussels

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
UCB	UCB SA Cap: 48.1B \| P/E: 36.9	EQUITY	BRU	EUR	BE0003739530	Active	📈